01-Dec-2011 - Lab21 Ltd

Lab21 Wins Biomedical Project of the Year Award

Lab21 Limited has won the BioNow Biomedical Project of the Year Award for its MycAssay product line.  The BioNow Biomedical Project of the Year Award recognises individuals or organisations who have demonstrated an innovative solution to a specific industry problem.

Lab21’s MycAssay Aspergillus and MycAssay Pneumocystis are the world’s first commercial PCR assays for pulmonary fungal infections.  A recent evaluation of MycAssay Aspergillus has shown it to be a sensitive and specific molecular test for the diagnosis of invasive aspergillus.

Hayden Jeffreys, Divisional Director of Products, Lab21 said: “This award for the MycAssay product line recognises the importance of Lab21’s tests for Aspergillus and Pneumocystis, the first products in what is rapidly becoming a portfolio of real-time PCR tests for serious invasive fungal diseases We are pleased with the adoption of these assays into routine use, already demonstrated by increasing sales into 14 countries.”

Facts, background information, dossiers
  • BioNow Biomedical P…
More about Lab21
  • News

    Lab21 announces sale of South Carolina Operations

    Lab21 Limited announced the sale of its laboratory operations based in South Carolina to Reedy Acquisitions Corp, an entity formed by the existing local management and South Carolina based investors. In addition to an immediate cash benefit for Lab21 Ltd, the sale will remove a loss-making ... more

    Lab21 secures European and USA patents for HCV drug resistance genotyping

    Lab21 Limited has secured new patents in Europe and the USA relating to Hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.   The patents cover technology allowing the genotypic identification of drug resistant mutat ... more

    Lab21 launches new lung cancer companion diagnostic service

    Lab21 Limited has launched a new Companion Diagnostic testing service for non-small cell lung cancer patients.The EML4-ALK companion diagnostic test for translocations in the ALK gene will allow physicians to select lung cancer patients likely to respond to ALK inhibitor therapy. The test u ... more

  • Companies

    Lab21 Ltd

    Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting drug discovery, healthcare and environmental monitoring. Its customers include healthcare providers, pharmaceutical and biotechnology companies, in addition to organisations that need to monitor thei ... more